Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| INmune Bio Inc. | INB03 | MUC4 expressing cancer | Phase 2 | Trial Planned | Subcutaneous | Oncology |
| INmune Bio Inc. | CORDStrom - (MissionEB) | Recessive Dystrophic Epidermolysis Bullosa (RDEB) | BLA Filing | Ongoing | Oral | Genetic Disorder |
| INmune Bio Inc. | AD02 | Alzheimer's Disease (AD) | Phase 2 | Data Released | Oral | Neurology |
| Innate Pharma S.A. | Avdoralimab | Bullous pemphigoid (BP) | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| Innate Pharma S.A. | Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |
| Innate Pharma S.A. | Lacutamab (IPH4102) combo with GemOx - (KILT) | Peripheral T-Cell Lymphoma (PTCL) | Phase 2 | Ongoing | Intravenous | Oncology |
| Innate Pharma S.A. | Lacutamab (IPH4102) - (TELLOMAK 3) | Mycosis Fungoides, Sézary Syndrome | Phase 3 | Trial Planned | Intravenous | Oncology |
| Innate Pharma S.A. | Monalizumab + Cetuximab - (INTERLINK-1) | Head and neck squamous cell carcinoma of the head and neck (SCCHN) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
